Cancer News and Research

Latest Cancer News and Research

BPA found in kids’ canned food

The chemical Bisphenol A (BPA) that is suspected to be harmful to babies may be found in several child-friendly canned foods. Breast Cancer Fund researchers tested for bisphenol A (BPA) in six products specifically marketed to children. Included in the list were such popular kid-targeted meals as Campbell’s “Disney Princess" soup with "shaped pasta with chicken in chicken broth” and Annie’s Homegrown certified organic “Cheesy Ravioli.” BPA, which is found in plastics, cash-register receipts, dental sealants and even money, has been linked in animal studies to a host of health ills, including possible cancers and developmental problems and early puberty.

22 Sep 2011

Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

22 Sep 2011

Cambridge Heart enters agreement with EO Medical for MTWA technology

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that it has executed an exclusive agreement with EO Medical Pte Ltd to distribute its HearTwave II System and proprietary Microvolt T-Wave Alternans (MTWA) software and Micro-V Alternans Sensors in Singapore upon regulatory approval.

22 Sep 2011

U.N. meeting on NCDs concludes with pledges to fight chronic diseases

World leaders on Tuesday "pledged to take wide-ranging action to prevent millions of deaths from cancer, diabetes, and heart and lung disease by tackling the key causes -- smoking, excessive drinking, lack of exercise and unhealthy diets dominated by fast food," but the "declaration approved at the first-ever General Assembly meeting on chronic diseases which ended Tuesday left unanswered the question of coordinating an international response to what the leaders called 'a challenge of epidemic proportions,'" the Associated Press/CBS News reports.

22 Sep 2011

Mass. hospitals oppose state penalties for preventable readmissions

Also in state news, a California news outlet reports on the difficult challenge hospitals face trying to recover overdue bill in a tough economy and another looks at efforts by a handful of hospitals to partner with churches to help reduce health care costs.

22 Sep 2011

New Poll: 9 out of 10 Ontarians would support an investment in lung health

According to a new Leger Marketing poll conducted for the Ontario Lung Association, 9 out of 10 of Ontarians would support the Ontario government investing in lung health today if it would save future healthcare spending.

22 Sep 2011

New and better understanding of blood vessel growth and angiogenesis in cancer

A new and better understanding of blood vessel growth and vascular development (angiogenesis) in cancer has been made possible by research carried out by a team of scientists from Moffitt Cancer Center, the University of Florida, Harvard University, Yale University and the Children's Hospital of Los Angeles.

22 Sep 2011

Mayo Clinic to develop Global Smoke-Free Worksite Challenge

Mayo Clinic announced today at the annual Clinton Global Initiative (CGI) meeting in New York City its partnership with other organizations to develop a Global Smoke-Free Worksite Challenge.

22 Sep 2011

Zymeworks announces completion of $8.1M financing

Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced the completion of a financing totaling $8.1 million.

22 Sep 2011

MD Anderson professor wins 2011 Julie and Ben Rogers Award for Excellence in Prevention

Lorna McNeill, Ph.D., assistant professor in the Department of Health Disparities Research at The University of Texas MD Anderson Cancer Center, is the recipient of the 2011 Julie and Ben Rogers Award for Excellence in Prevention.

22 Sep 2011

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

22 Sep 2011

HSPH receives CDC grant to evaluate HIV combination prevention initiative in Botswana

A new four-year, $20 million grant from the U.S. Centers for Disease Control and Prevention (CDC) will enable Harvard School of Public Health (HSPH) researchers to evaluate the impact and cost-effectiveness of a unique combination of HIV prevention strategies in Botswana.

22 Sep 2011

Methylphenidate drug may induce arousal from general anesthesia

Administration of the commonly used stimulant drug methylphenidate (Ritalin) was able to speed recovery from general anesthesia in an animal study conducted at Massachusetts General Hospital.

22 Sep 2011

Stanford Hospital & Clinics inaugurates new Brain Tumor Center

Today, Stanford Hospital & Clinics inaugurates its new Brain Tumor Center, framing its considerable corps of top-notch specialists into a treatment team driven by expertise, experience and compassion.

22 Sep 2011

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-032, a broadly protective, fully human monoclonal antibody for the treatment of influenza A virus.

22 Sep 2011

Early ART can be cost-effective and decrease mortality in HIV patients

Researchers at Weill Cornell Medical College and GHESKIO have shown that early treatment of HIV not only saves lives but is also cost-effective. Results are published in today's edition of PLoS Medicine.

22 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Sanofi-aventis sponsors People vs. Cancer initiative

Sanofi-aventis Canada is proud to be the national sponsor of People vs. Cancer, a speaking tour of three Canadian universities featuring Stephen Lewis, former Canadian Ambassador to the United Nations and United Nations Special Envoy for HIV/AIDS in Africa.

22 Sep 2011

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate), is effective not only in decreasing tumor size but also in reducing the severity of side effects that often accompany a cancer diagnosis.

22 Sep 2011

Three Johns Hopkins scientists receive NIH Director's New Innovator Awards

A pioneer in the field of epigenetics who has been spearheading the use of genome-wide technology for epigenetics research, a researcher who has revealed a weakness in the tuberculosis bacterium that makes it more susceptible to antibiotics, and a scientist who seeks to revolutionize new methods for toxicological testing to improve human health and reduce animal testing have received Director's Awards from the National Institutes of Health.

22 Sep 2011